Key facts
- This page summarizes Ofir Levi's Form 4 filing for Vallon Pharmaceuticals, Inc. (GRI).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 18 May 2021, 16:08.
Ofir Levi - 14 May 2021 Form 4 Insider Report for Vallon Pharmaceuticals, Inc. (GRI)
- Reporting relationship
- Director
- Issuer ticker
- GRI
- Reported as of
- 14 May 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ David Baker, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Ofir Levi filed Form 4 for Vallon Pharmaceuticals, Inc. (GRI) on 18 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GRI
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- Price
- $0.000000
- Shares after
- 15,000
- Date
- 14 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $3.66
- Footnotes
- F1
GRI
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 14 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $3.66
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The stock option vests as to 50% of the underlying shares of common stock on June 30, 2021, then in two equal installments on September 30, 2021 and December 31, 2021, such that the stock option fully vests on December 31, 2021.
Footnote F2
The stock option vests in 24 equal monthly installments such that the stock option is fully vested on the second annual anniversary of the date of grant.